<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-111 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-111</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-111</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-2.html">extraction-schema-2</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <p><strong>Paper ID:</strong> paper-6033885</p>
                <p><strong>Paper Title:</strong> Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients</p>
                <p><strong>Paper Abstract:</strong> OBJECTIVE: Epidermal growth factor receptor is involved in the pathogenesis of non-small cell lung cancer and has recently emerged as an important target for molecular therapeutics. The KRAS oncogene also plays an important role in the development of lung cancer. The aim of this study was to evaluate the frequency of epidermal growth factor receptor and KRAS mutations in a population of Brazilian patients with non-small cell lung cancer. METHODS: A total of 207 specimens from Brazilian patients with non-small cell lung cancer were analyzed for activating epidermal growth factor receptor and KRAS somatic mutations, and their associations with clinicopathological characteristics (including age, gender, ethnicity, smoking habits, and histological subtype) were examined. RESULTS: We identified 63 cases (30.4%) with epidermal growth factor receptor mutations and 30 cases (14.6%) with KRAS mutations. The most frequent epidermal growth factor receptor mutation we detected was a deletion in exon 19 (60.3%, 38 patients), followed by an L858R amino acid substitution in exon 21 (27%, 17 patients). The most common types of KRAS mutations were found in codon 12. There were no significant differences in epidermal growth factor receptor or KRAS mutations by gender or primary versus metastatic lung cancer. There was a higher prevalence of KRAS mutations in the non-Asian patients. Epidermal growth factor receptor mutations were more prevalent in adenocarcinomas than in non-adenocarcinoma histological types. Being a non-smoker was significantly associated with the prevalence of epidermal growth factor receptor mutations, but the prevalence of KRAS mutations was significantly associated with smoking. CONCLUSIONS: This study is the first to examine the prevalence of epidermal growth factor receptor and KRAS mutations in a Brazilian population sample with non-small cell lung cancer.</p>
                <p><strong>Cost:</strong> 0.013</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e111.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e111.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Brazilian NSCLC cohort</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Brazilian non-small cell lung cancer patient cohort (this study)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A series of 207 Brazilian NSCLC patient specimens (all five geographic macroregions of Brazil represented) analyzed for EGFR (exons 18-21) and KRAS (exon 2, codons 12/13) somatic mutations; used as the primary dataset in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Brazilian NSCLC patients (n=207) from all five geographic regions of Brazil; includes 13 patients with Asian ancestry and 194 non-Asian patients</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>30.4% overall (63/207); exon 19 deletions 60.3% of EGFR-mutant cases (38/63), exon 21 L858R 27% (17/63); exon 18 codon 719 point mutations 7.9% (5/63); exon 20 insertions 4.8% (3/63); one L861Q in exon 21</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Within study: Asian ancestry patients (n=13) vs non-Asian patients (n=194) â€” no statistically significant difference in EGFR mutation frequency reported; KRAS mutations (30/206, 14.6%) were present only in non-Asian patients in this cohort (all 30 KRAS-mutant cases were non-Asian).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>EGFR: exon 19 deletions, exon 21 L858R, exon 18 codon 719 point mutations, exon 20 in-frame insertions, L861Q (exon 21). KRAS: codon 12 mutations predominantly G12C (50%) and G12D (20%).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_association</strong></td>
                            <td>EGFR mutations significantly enriched in never-smokers (45.5% of never-smokers vs 18.9% of current/ex-smokers in this cohort); KRAS mutations significantly associated with smoking (frequency ~2.7x higher in smokers).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>No environmental exposures were invoked to explain EGFR frequency differences in this cohort; tobacco-related polycyclic aromatic hydrocarbons (PAHs) are mentioned as an explanation for certain KRAS mutation types (cysteine substitutions) but not for EGFR differences.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>Authors suggest Brazil's extensive historical admixture (Amerindian, European, African, Asian) as a likely contributor to the high EGFR mutation rate observed, implying a role for underlying genetic background rather than regional environment.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Paper reiterates that EGFR activating mutations sensitize tumors to EGFR tyrosine kinase inhibitors and that KRAS activating mutations (downstream of EGFR) confer resistance; however, no specific molecular mechanism for ethnic differences in EGFR mutation acquisition is proposed beyond genetic predisposition.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_subtype</strong></td>
                            <td>Non-small cell lung cancer (NSCLC) overall; EGFR mutations were significantly more prevalent in adenocarcinomas (33.7%) than in non-adenocarcinoma subtypes (15.8%).</td>
                        </tr>
                        <tr>
                            <td><strong>demographic_factors</strong></td>
                            <td>Cohort demographics: 87 men, 120 women; mean age 62.8 (range 25-91). Although EGFR mutations are often reported elsewhere to be more common in younger females, this study found no statistically significant difference by age or gender (EGFR 33.3% in females vs 26.4% in males, not significant). The small number of Asian-ancestry patients (n=13) is noted.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation</strong></td>
                            <td>Proposed explanations for the relatively high EGFR mutation frequency in this Brazilian sample: (1) genetic ancestry/admixture in Brazil (mixture of Amerindian, European, African, and Asian ancestries) as a driver of mutation prevalence; (2) association of EGFR mutations with never-smoking status which may be more common in subgroups; the authors argue genetic rather than geographic/environmental causes because prior studies found EGFR association with ethnicity but not geographic exposures.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_confounds</strong></td>
                            <td>Authors note limitations and possible confounds: small number of patients with Asian ancestry (n=13) limiting power to detect ethnic differences; case selection bias because all specimens were submitted for EGFR/KRAS testing (not population-based sampling); literature shows inconsistent age/gender associations across studies; the paper also cites prior reports finding no geographic associations (suggesting complexity beyond simple geographic/environmental explanations).</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e111.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e111.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>East Asian populations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>East Asian lung cancer patients (compiled literature)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Multiple referenced studies report substantially higher EGFR mutation frequencies in East Asian NSCLC patients compared with Western populations; EGFR-mutant tumors are also reported to be enriched in never-smokers and adenocarcinomas in these populations.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>East Asian NSCLC patients (literature-compiled population; specific studies cited include Asian cohorts in cited references)</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Reported in the paper as varying from ~27% to 60% in Asians (intro and discussion cite ranges from multiple prior studies); elsewhere in the discussion they report Asian ranges of ~30-50% when comparing to the Brazilian rate.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Compared in text to Europeans (8-13%), African and white Americans (12-16%), and the Brazilian cohort (30.4%); reported Asian frequencies markedly higher than European/American ranges.</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Same EGFR hotspot distribution noted for Asians: exon 19 deletions and exon 21 L858R are the dominant activating mutations (exon 19 deletions and L858R together represent the majority).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_association</strong></td>
                            <td>EGFR mutations in East Asian cohorts are described as more common in never-smokers; the paper cites literature linking EGFR-mutant NSCLC to 'never-smoker' status particularly in Asians.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>Paper states that no geographic/environmental associations have been consistently found in prior work, arguing against simple environmental explanations for higher Asian rates.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>Paper (citing prior work) suggests that the greater EGFR mutation prevalence in East Asians is likely related to genetic background rather than environmental exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>No specific molecular mechanism exclusive to East Asians is provided in this paper; the text emphasizes associative patterns (ethnicity-linked prevalence) rather than mechanistic causation.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_subtype</strong></td>
                            <td>Primarily adenocarcinoma (EGFR mutations concentrated in adenocarcinomas in Asian series as well).</td>
                        </tr>
                        <tr>
                            <td><strong>demographic_factors</strong></td>
                            <td>Literature-cited patterns: enrichment in females and in younger patients reported in some studies, though findings are not universal.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation</strong></td>
                            <td>Authors summarize prevailing interpretation from literature: ethnicity-linked genetic predisposition (East Asian ancestry) as the most plausible explanation for higher EGFR mutation frequencies rather than environmental or geographic exposures.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_confounds</strong></td>
                            <td>Paper notes that some studies find inconsistent demographic associations and that geographic/environmental explanations have not been consistently supported; also implies that admixture in populations (such as Brazil) complicates simple ethnicity-based categorization.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e111.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e111.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>European populations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>European lung cancer patients (compiled literature)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Referenced literature reports lower EGFR mutation prevalence in European NSCLC patients compared with East Asian patients.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>European NSCLC patients (literature-derived ranges cited in the paper)</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Reported ranges in paper: approximately 8-13% in Europeans.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Compared with Asians (27-60% reported) and Brazilian cohort (30.4%); Europeans have lower reported frequencies.</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Same predominant mutations (exon 19 deletions and exon 21 L858R) are reported across populations; paper cites compiled distribution across exons from pooled studies.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_association</strong></td>
                            <td>Paper reiterates general pattern from literature that EGFR mutations are more common in never-smokers, which affects observed frequencies in different populations.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>No specific environmental factor is cited as explaining the lower European rates; paper emphasizes lack of clear geographic/environmental correlation.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>Lower European rates are implied to reflect different genetic background (ancestry) compared to East Asians.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Not specifically proposed beyond general tumor biology (EGFR activating mutations confer TKI sensitivity).</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_subtype</strong></td>
                            <td>Primarily adenocarcinoma where EGFR mutations concentrate.</td>
                        </tr>
                        <tr>
                            <td><strong>demographic_factors</strong></td>
                            <td>Not detailed beyond general literature patterns (e.g., associations with never-smoking).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation</strong></td>
                            <td>Paper suggests ethnic/genetic background differences as primary explanation for lower European EGFR mutation prevalence compared to Asians.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_confounds</strong></td>
                            <td>Inter-study heterogeneity, varying study designs, and potential selection biases across cohorts are implicit confounds; paper does not present direct mechanistic counterevidence.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e111.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e111.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>African and white Americans</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>African American and white American lung cancer patients (compiled literature)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Referenced literature reports EGFR mutation frequencies in African and white American NSCLC patients in the low-mid teens percentage range.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>African American and white American NSCLC patients (literature-cited ranges)</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Reported in the paper as approximately 12-16% in African and white Americans.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Compared to Asians (higher) and Europeans (similar to some European ranges); paper contrasts these frequencies with the Brazilian cohort (~30.4%).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Predominant EGFR hotspot mutations (exon 19 deletions, exon 21 L858R) as in other populations.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_association</strong></td>
                            <td>EGFR mutations generally more prevalent in never-smokers; smoking prevalence differences can influence population-level frequencies.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>No environmental factors are proposed in the paper to explain the patterns in these American populations.</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>Differences are attributed by the authors (citing prior work) more to genetic/ancestral background than to environment.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>Not specifically addressed for these populations beyond general EGFR/KRAS biology.</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_subtype</strong></td>
                            <td>Adenocarcinoma is the histologic subtype most enriched for EGFR mutations.</td>
                        </tr>
                        <tr>
                            <td><strong>demographic_factors</strong></td>
                            <td>Not detailed specifically in the paper for these groups.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation</strong></td>
                            <td>Authors imply that lower EGFR mutation prevalence in these groups relative to East Asians is due to differences in genetic background/ancestry.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_confounds</strong></td>
                            <td>Inter-study variability and sampling differences across studies may confound direct comparisons; paper does not present direct mechanistic evidence.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e111.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e111.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>KRAS mutation ethnic pattern</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Ethnic differences in KRAS mutation frequency (compiled literature and this study)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>KRAS mutations tend to be more frequent in Caucasian (Western) NSCLC patients and strongly associated with smoking; this study observed KRAS mutations exclusively in non-Asian patients in the Brazilian cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Cited literature: Caucasians and Asians; this paper: Brazilian cohort (KRAS mutations observed in non-Asian patients only).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Literature: KRAS in Caucasians 20-30% of lung adenocarcinomas vs Asians 5-20%; this study: KRAS 14.6% overall, all 30 KRAS-mutant cases were in non-Asian patients.</td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>KRAS: primarily codon 12 mutations in this study (G12C 50%, G12D 20%); ~97% of NSCLC KRAS mutations affect codons 12 and 13 per literature cited.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_association</strong></td>
                            <td>KRAS mutations are strongly associated with smoking; in this study smokers had ~2.7x higher KRAS mutation frequency and KRAS mutation types (cysteine substitutions) are attributed to tobacco-derived PAHs.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>Tobacco smoke (polycyclic aromatic hydrocarbons) invoked as an environmental mutagenic factor driving characteristic KRAS mutations (cysteine substitutions).</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td>Ethnic differences in KRAS frequency are reported in prior studies; this paper suggests these differences exist but does not propose specific germline genetic variants.</td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td>KRAS is downstream of EGFR; activating KRAS mutations render EGFR TKI therapy ineffective (mechanistic resistance).</td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_subtype</strong></td>
                            <td>Primarily adenocarcinoma (KRAS mutations enriched in lung adenocarcinomas).</td>
                        </tr>
                        <tr>
                            <td><strong>demographic_factors</strong></td>
                            <td>Smoking status is the major demographic/behavioral correlate; ethnicity also correlates with KRAS frequency in literature (higher in Caucasians).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation</strong></td>
                            <td>Combination of smoking-related mutagenesis (PAHs) producing specific KRAS mutation spectra and differences in population smoking patterns and genetic background explain ethnic variation in KRAS frequencies.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_confounds</strong></td>
                            <td>This study's finding that all KRAS mutations were in non-Asian patients could be influenced by small Asian sample size (n=13) and selection bias of tested specimens; inter-study heterogeneity in KRAS frequency across the literature is noted.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib <em>(Rating: 2)</em></li>
                <li>EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib <em>(Rating: 2)</em></li>
                <li>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma <em>(Rating: 2)</em></li>
                <li>KRAS mutations and resistance to EGFR-TKIs treatment in patients with nonsmall cell lung cancer: a meta-analysis of 22 studies <em>(Rating: 2)</em></li>
                <li>Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers <em>(Rating: 2)</em></li>
                <li>Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer <em>(Rating: 2)</em></li>
                <li>Distinct epidermal growth factor receptor and KRAS mutation patterns in nonsmall cell lung cancer patients with different tobacco exposure and clinicopathologic features <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>